Atlas Trials

Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD

Clinical trial NCT02176031 · COMPLETED

Trial details

NCT number
NCT02176031
Sponsor
Dana-Farber Cancer Institute
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Graft Versus Host Disease
Start date
2015-01-01
Primary completion
2019-02-01
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.